U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    RAD51C RAD51 paralog C [ Homo sapiens (human) ]

    Gene ID: 5889, updated on 11-Apr-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    Variants in the first methionine of RAD51C are homologous recombination proficient due to an alternative start site.

    Variants in the first methionine of RAD51C are homologous recombination proficient due to an alternative start site.
    Rein HL, Bernstein KA.,

    03/5/2024
    RAD51C-XRCC3 structure and cancer patient mutations define DNA replication roles.

    RAD51C-XRCC3 structure and cancer patient mutations define DNA replication roles.
    Longo MA, Roy S, Chen Y, Tomaszowski KH, Arvai AS, Pepper JT, Boisvert RA, Kunnimalaiyaan S, Keshvani C, Schild D, Bacolla A, Williams GJ, Tainer JA, Schlacher K., Free PMC Article

    09/8/2023
    Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.

    Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Hu C, Nagaraj AB, Shimelis H, Montalban G, Lee KY, Huang H, Lumby CA, Na J, Susswein LR, Roberts ME, Marshall ML, Hiraki S, LaDuca H, Chao E, Yussuf A, Pesaran T, Neuhausen SL, Haiman CA, Kraft P, Lindstrom S, Palmer JR, Teras LR, Vachon CM, Yao S, Ong I, Nathanson KL, Weitzel JN, Boddicker N, Gnanaolivu R, Polley EC, Mer G, Cui G, Karam R, Richardson ME, Domchek SM, Yadav S, Hruska KS, Dolinsky J, Weroha SJ, Hart SN, Simard J, Masson JY, Pang YP, Couch FJ., Free PMC Article

    08/4/2023
    Structural insights into BCDX2 complex function in homologous recombination.

    Structural insights into BCDX2 complex function in homologous recombination.
    Rawal Y, Jia L, Meir A, Zhou S, Kaur H, Ruben EA, Kwon Y, Bernstein KA, Jasin M, Taylor AB, Burma S, Hromas R, Mazin AV, Zhao W, Zhou D, Wasmuth EV, Greene EC, Sung P, Olsen SK.,

    07/27/2023
    Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor.

    Structure and function of the RAD51B-RAD51C-RAD51D-XRCC2 tumour suppressor.
    Greenhough LA, Liang CC, Belan O, Kunzelmann S, Maslen S, Rodrigo-Brenni MC, Anand R, Skehel M, Boulton SJ, West SC., Free PMC Article

    07/27/2023
    SNV/indel hypermutator phenotype in biallelic RAD51C variant: Fanconi anemia.

    SNV/indel hypermutator phenotype in biallelic RAD51C variant: Fanconi anemia.
    Zemet R, Du H, Gambin T, Lupski JR, Liu P, Stankiewicz P.,

    05/30/2023
    UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.

    UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.
    Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M, Consensus meeting attendees, Lalloo F., Free PMC Article

    04/26/2023
    Functional analysis of germline RAD51C missense variants highlight the role of RAD51C in replication fork protection.

    Functional analysis of germline RAD51C missense variants highlight the role of RAD51C in replication fork protection.
    Kolinjivadi AM, Chong ST, Choudhary R, Sankar H, Chew EL, Yeo C, Chan SH, Ngeow J.

    04/7/2023
    Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer.

    Germline mutations in RAD51C and RAD51D and hereditary predisposition to ovarian cancer.
    Soukupová J, Lhotová K, Janatová M, Kleiblová P, Vočka M, Foretová L, Zikán M, Kleibl Z.

    03/15/2023
    Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence.

    Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence.
    Lee A, Mavaddat N, Cunningham A, Carver T, Ficorella L, Archer S, Walter FM, Tischkowitz M, Roberts J, Usher-Smith J, Simard J, Schmidt MK, Devilee P, Zadnik V, Jürgens H, Mouret-Fourme E, De Pauw A, Rookus M, Mooij TM, Pharoah PP, Easton DF, Antoniou AC., Free PMC Article

    12/3/2022
    Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.

    Homologous recombination-deficient mutation cluster in tumor suppressor RAD51C identified by comprehensive analysis of cancer variants.
    Prakash R, Rawal Y, Sullivan MR, Grundy MK, Bret H, Mihalevic MJ, Rein HL, Baird JM, Darrah K, Zhang F, Wang R, Traina TA, Radke MR, Kaufmann SH, Swisher EM, Guérois R, Modesti M, Sung P, Jasin M, Bernstein KA., Free PMC Article

    10/1/2022
    BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma.

    BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma.
    Abdallah R, Zhao S, Garinet S, Hormigos K, Le Corre D, Cros J, Perez Toralla K, Bats AS, Augustin J, Bachet JB, Taly V, Blons H, Taieb J, Laurent-Puig P.

    06/18/2022
    A decade of RAD51C and RAD51D germline variants in cancer.

    A decade of RAD51C and RAD51D germline variants in cancer.
    Boni J, Idani A, Roca C, Feliubadaló L, Tomiak E, Weber E, Foulkes WD, Orthwein A, El Haffaf Z, Lazaro C, Rivera B.

    05/7/2022
    Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.

    Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
    Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Ghamsari MRE, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL.

    01/8/2022
    Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C.

    Massively parallel sequencing in hereditary prostate cancer families reveals a rare risk variant in the DNA repair gene, RAD51C.
    Marthick JR, Raspin K, Foley GR, Blackburn NB, Banks A, Donovan S, Malley RC, Field MA, Stanford JL, Ostrander EA, FitzGerald LM, Dickinson JL.

    12/18/2021
    TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.

    TAZ maintains telomere length in TNBC cells by mediating Rad51C expression.
    Yang L, Wang B, Jiao X, Zhou C, Chen S, Gao X, Sun W, Song S, Li J, Liu J, Wang Y, Liu P., Free PMC Article

    12/18/2021
    Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.

    Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
    Sullivan MR, Prakash R, Rawal Y, Wang W, Sung P, Radke MR, Kaufmann SH, Swisher EM, Bernstein KA, Jasin M., Free PMC Article

    12/4/2021
    Association of RAD51C germline mutations with breast cancer among Bahamians.

    Association of RAD51C germline mutations with breast cancer among Bahamians.
    Bagherzadeh M, Szymiczek A, Donenberg T, Butler R, Hurley J, Narod SA, Akbari MR.

    08/7/2021
    Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.

    Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.
    Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, Horváth J, Kast K, Niederacher D, Turnbull C, Houlston R, Hanson H, Loveday C, Dolinsky JS, LaDuca H, Ramus SJ, Menon U, Rosenthal AN, Jacobs I, Gayther SA, Dicks E, Nevanlinna H, Aittomäki K, Pelttari LM, Ehrencrona H, Borg Å, Kvist A, Rivera B, Hansen TVO, Djursby M, Lee A, Dennis J, Bowtell DD, Traficante N, Diez O, Balmaña J, Gruber SB, Chenevix-Trench G, Investigators K, Jensen A, Kjær SK, Høgdall E, Castéra L, Garber J, Janavicius R, Osorio A, Golmard L, Vega A, Couch FJ, Robson M, Gronwald J, Domchek SM, Culver JO, de la Hoya M, Easton DF, Foulkes WD, Tischkowitz M, Meindl A, Schmutzler RK, Pharoah PDP, Antoniou AC., Free PMC Article

    05/1/2021
    A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.

    A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.
    Dawson LM, Smith KN, Werdyani S, Ndikumana R, Penney C, Wiede LL, Smith KL, Pater JA, MacMillan A, Green J, Drover S, Young TL, O'Rielly DD., Free PMC Article

    03/27/2021
    BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.

    BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases.
    Suszynska M, Ratajska M, Kozlowski P., Free PMC Article

    01/2/2021
    Sequential role of RAD51 paralog complexes in replication fork remodeling and restart.

    Sequential role of RAD51 paralog complexes in replication fork remodeling and restart.
    Berti M, Teloni F, Mijic S, Ursich S, Fuchs J, Palumbieri MD, Krietsch J, Schmid JA, Garcin EB, Gon S, Modesti M, Altmeyer M, Lopes M., Free PMC Article

    09/12/2020
    This study provides evidence that germline loss-of-function variants of RAD51C are associated with hereditary breast cancer, particularly triple-negative type. RAD51C-null breast cancers possess similar genomic and clinical features to BRCA1-null cancers and may also be vulnerable to DNA double-strand break inducing chemotherapies and poly ADP-ribose polymerase inhibitors.

    Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.
    Li N, McInerny S, Zethoven M, Cheasley D, Lim BWX, Rowley SM, Devereux L, Grewal N, Ahmadloo S, Byrne D, Lee JEA, Li J, Fox SB, John T, Antill Y, Gorringe KL, James PA, Campbell IG., Free PMC Article

    06/13/2020
    Evidence that RAD51C-ALKBH3 interaction stimulates ALKBH3-mediated repair of methyl-adduct located within 3'-tailed DNA, which serves as a substrate for the RAD51 recombinase. The lack of RAD51C-ALKBH3 interaction affects ALKBH3 function in vitro and in vivo.

    Human RAD51 paralogue RAD51C fosters repair of alkylated DNA by interacting with the ALKBH3 demethylase.
    Mohan M, Akula D, Dhillon A, Goyal A, Anindya R., Free PMC Article

    06/6/2020
    Low RAD51C expression is associated with sporadic Gastric Cancer than in early-onset or familial Gastric Cancer.

    Expression of DNA Damage Response Markers in Early-Onset or Familial Gastric Cancers.
    Kim HS, Kim JW, Hwang IG, Lee HS, Kim WH., Free PMC Article

    12/7/2019
    firstprevious page of 4 nextlast